Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 2Unknown 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 544Neoplasms 384Carcinoma, Non-Small-Cell Lung 325Colorectal Neoplasms 296Lung Neoplasms 237Prostatic Neoplasms 220Carcinoma, Hepatocellular 213Stomach Neoplasms 155Pancreatic Neoplasms 155Leukemia, Myeloid, Acute 141Uterine Cervical Neoplasms 132Multiple Myeloma 130Recurrence 120Rectal Neoplasms 114Ovarian Neoplasms 109Neoplasm Metastasis 105Squamous Cell Carcinoma of Head and Neck 98Head and Neck Neoplasms 91Triple Negative Breast Neoplasms 87Esophageal Neoplasms 84Glioblastoma 82Endometrial Neoplasms 80Small Cell Lung Carcinoma 79Brain Neoplasms 79Colonic Neoplasms 78Melanoma 71Precursor Cell Lymphoblastic Leukemia-Lymphoma 65Hematologic Neoplasms 65Glioma 63Disease 60

Interventions

pembrolizumab 1lenvatinib 1Paclitaxel 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Advanced Non-squamous Non-small-cell Lung Cancer × Clear all
NCT06028633 2023-09-13

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Peking University First Hospital

Phase 2 Not yet recruiting
28 enrolled
Thoracic

Advanced Non-squamous Non-small-cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡